Treatment of infected hip arthroplasty with antibiotic-impregnated calcium hydroxyapatite.
ABSTRACT We reviewed the treatment of infected hip arthroplasty with antibiotic-impregnated calcium hydroxyapatite (CHA) ceramic blocks. Seven consecutive patients consisting of 2 men and 5 women with an average age of 65 years were followed up for an average of 5.0 years. All patients received resection arthroplasty and thorough debridement, followed by implantation of antibiotic-impregnated CHA ceramic. Two-stage revision was performed in all patients. There was no evidence of a recurrent infection in 6 patients. The remaining one patient underwent an additional debridement 2 years after the second stage. This patient was free of infection at the time of the latest follow-up. Antibiotic-impregnated CHA ceramic is thus considered to be an excellent drug delivery system for the infected hip arthroplasty.
Article: Amelioration of anemia in the ICGN mouse, a renal anemia model, with a subcutaneous bolus injection of erythropoietin adsorbed to hydroxyapatite matrix.[show abstract] [hide abstract]
ABSTRACT: The recombinant human erythropoietin (rhEPO) is used for the treatment of patients with renal anemia. However, rhEPO should be administered subcutaneously or intravenously three times a week. The repetitive injections of rhEPO result in burdens to patients. To resolve this problem, we investigated the sustaining release methods using an rhEPO-hydroxyapatite (HAp) made by spray-drying technique as the drug delivery system. Two types of rhEPO-HAp formulations were prepared; zinc (Zn) formulation and Zn and poly-L-lactic acid (PLA) formulation. These formulations were examined in genetically anemic model, ICGN (ICR-derived glomerulonephritis) mice. According to in vivo release test of rhEPO from HAp in ICGN mice, elevated plasma concentration of rhEPO could be maintained for more than 7 days. These mice showed the amelioration of anemia for more than 3 weeks post-administration without causing any side effect. In conclusion, Zn or Zn/PLA formulation of HAp was considered to be one of the useful carriers of rhEPO for long-term improvement of anemia.Journal of Veterinary Medical Science 10/2009; 71(10):1365-71. · 0.85 Impact Factor